Prime Medicine ($PRME) Stock Forecast: Up 6.9% Today

What is Prime Medicine?

Prime Medicine Inc (PRME) is a biotech firm focused on advancing genetic treatments, particularly through its Prime Editing platform. The company has shown revenue growth in fiscal 2025 despite incurring a large net loss due to heavy R&D investment.

Why is Prime Medicine going up?

PRME stock is up 6.9% on Jun 17, 2026 13:55

• PRME stock experienced a strong bullish movement likely due to positive analyst earnings forecasts and a majority "Buy" rating.
• The company's revenue growth in fiscal 2025 despite a net loss could have instilled confidence in investors about its long-term potential.
• Participation in prestigious events like the Goldman Sachs 47th Annual Global Healthcare Conference may have also contributed to the positive market sentiment surrounding PRME.
• Overall, the bullish movement could be attributed to a combination of favorable earnings forecasts, revenue growth, and industry recognition.

PRME Price Chart

PRME Technical Analysis

PRME News

Prime Medicine Inc (PRME) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Prime Medicine Inc (PRME), highlighting its earnings forecast score of 8.00 within the Biotechnology & Medical Research industry. Analysts have set an average price target of $6.00 for PRME, with a majority recommending a "Buy" rating. The report also details expected revenue, EPS for the next quarter, and past performance.

https://www.tradingkey.com/markets/stocks/nasdaq-prme/earnings

Ocular Therapeutix vs. Prime Medicine: A 2026 Analysis of Medical Innovation Stocks - News and Statistics

This article analyzes two medical innovation companies, Ocular Therapeutix (NASDAQ:OCUL) and Prime Medicine (NASDAQ:PRME), in 2026. Ocular Therapeutix, focusing on ophthalmic drug delivery, reported a revenue decline and significant net loss in fiscal 2025 but has strong liquidity. Prime Medicine, a biotech firm advancing genetic treatments, showed revenue growth in fiscal 2025 despite incurring a large net loss due to heavy R&D investment in its early-stage Prime Editing platform.

https://www.indexbox.io/blog/ocular-therapeutix-vs-prime-medicine-balancing-revenue-and-therapeutic-potential-in-2026/

Transcript : Prime Medicine, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 10

This article is a transcript from Prime Medicine, Inc.'s presentation at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, at 10:40 AM. The presentation featured Dr. Allan Ryan, CEO of Prime Medicine. The full content of the transcript is reserved for subscribers.

https://www.marketscreener.com/news/transcript-prime-medicine-inc-presents-at-goldman-sachs-47th-annual-global-healthcare-conference-ce7f5cdbdd80f12c

Trending Today

Adobe Inc. ($ADBE) Stock Forecast: Down 5.4% Today

Upwork Inc. ($UPWK) Stock Forecast: Down 5.2% Today

CarMax Inc ($KMX) Stock Forecast: Down 9.9% Today

Gap Inc. ($GAP) Stock Forecast: Down 3.6% Today

Alexandria Real Estate Equities Inc. ($ARE) Stock Forecast: Down 5.4% Today

Baxter International Inc. ($BAX) Stock Forecast: Down 5.1% Today

Franklin Resources Inc. ($BEN) Stock Forecast: Up 0.4% Today

Moderna Inc. ($MRNA) Stock Forecast: Up 10.8% Today

Robinhood Inc. ($HOOD) Stock Forecast: Up 9.4% Today

Meta Platforms, Inc. ($META) Stock Forecast: Down 5.2% Today

Prime Medicine Price History

16.05.2026 - PRME Stock was down 5.9%

• Prime Medicine reported a large net loss due to heavy R&D investment in its Prime Editing platform, which might have concerned investors and led to a bearish movement in the stock.
• The revenue growth in fiscal 2025 was overshadowed by the significant net loss, indicating that investors are cautious about the company's profitability in the near term.
• The presentation at the Goldman Sachs conference did not seem to have a positive impact on the stock, as the market might be waiting for concrete results or financial stability before reacting positively to the company's initiatives.

29.04.2026 - PRME Stock was up 6.5%

• Presence at the Jefferies Global Healthcare Conference probably boosted investor confidence in Prime Medicine's cutting-edge gene editing therapies.
• Concentration on creating curative genetic treatments for a range of medical fields might have garnered favorable interest from investors.
• The company's dedication to accurately fixing genetic mutations could have established it as a frontrunner in the biotechnology industry, fueling positive sentiment and stock price increase.

14.04.2026 - PRME Stock was down 5.1%

• PRME's Q1 report showed a loss and revenue below estimates, causing a downward market trend.
• The EPS of (28c) compared to the anticipated (25c) may have disappointed investors, influencing the bearish movement.
• While revenue exceeded predictions, the overall financial performance falling short of analysts' expectations could have triggered negativity among investors.
• H.C. Wainwright's hold rating and the projection of declining earnings along with significant revenue growth could have increased uncertainty, impacting PRME's stock price adversely.

08.04.2026 - PRME Stock was down 0.2%

• Today's decline in PRME stock could be attributed to various factors:
• The Q1 2026 net loss exceeding expectations might have sparked worries among investors regarding the company's financial stability and operational longevity.
• Despite positive regulatory filings and anticipated clinical data progress in its pipeline programs, the market could have been underwhelmed by the absence of significant revenue-generating milestones in the immediate future.
• While the hiring of a new CFO could be seen as a positive move for the company's leadership, it might have introduced an element of uncertainty affecting investor sentiment.
• Overall, today's market sentiment towards PRME appears to have been swayed more by immediate financial performance concerns rather than the future promise of its gene-editing technologies.

17.05.2026 - PRME Stock was up 6.9%

• PRME stock experienced a strong bullish movement likely due to positive analyst earnings forecasts and a majority "Buy" rating.
• The company's revenue growth in fiscal 2025 despite a net loss could have instilled confidence in investors about its long-term potential.
• Participation in prestigious events like the Goldman Sachs 47th Annual Global Healthcare Conference may have also contributed to the positive market sentiment surrounding PRME.
• Overall, the bullish movement could be attributed to a combination of favorable earnings forecasts, revenue growth, and industry recognition.

07.04.2026 - PRME Stock was down 5.5%

• A rating shift from "strong sell" to "sell" by a prominent financial organization likely influenced the downward movement of PRME stock.
• Disclosures made to the SEC possibly unveiled worrisome details or future prospects, prompting a negative reaction from investors and subsequent stock depreciation.
• Despite significant institutional ownership and its cutting-edge Prime Editing technology, a change in market sentiment due to recent events has led to today's bearish trend for PRME.

07.04.2026 - PRME Stock was down 9.6%

• The bearish movement in PRME stock today could be attributed to several factors:
• Despite reporting a narrower net loss and a cash runway into 2027, investors might have been disappointed by the lack of significant revenue generation in the recent financial results.
• The downgrade of PRME from a "strong sell" to a "sell" rating by an industry analyst could have influenced market sentiment negatively, leading to increased selling pressure on the stock.
• The focus on regulatory filings for PM577 and PM647 in 2026, with clinical data expected in 2027, might have raised concerns among investors about the timeline and success of these programs, leading to a cautious approach towards the stock.
• The overall market sentiment towards biotechnology companies or the healthcare sector as a whole might have been bearish today, impacting PRME along with other similar stocks in the industry.

17.03.2026 - PRME Stock was up 5.7%

• PRME stock saw a notable uptrend following the announcement of Svetlana Makhni as the new Chief Financial Officer.
• Investors reacted favorably to Makhni's extensive background in biotech and healthcare finance, showing trust in her financial oversight abilities for the upcoming clinical trials.
• Makhni's appointment is viewed as pivotal for Prime Medicine's financial strategies, investor communications, and corporate expansion, setting the stage for future growth and medical progress.
• CEO Allan Reine stepping down from the financial officer position, ensuring clear financial and operational leadership separation, reinforced the market's optimism about PRME's future outlook.

04.05.2026 - PRME Stock was up 11.9%

• The bullish movement in PRME stock today could be attributed to the positive market sentiment generated by the announcement of the CEO's participation in the prestigious Goldman Sachs 47th Annual Global Healthcare Conference.
• Investors may view Prime Medicine's focus on developing innovative genetic therapies and its potential to repair a wide range of genetic mutations as a promising opportunity for growth and advancement in the biotechnology sector.
• The live audio webcast of the presentation may have increased investor confidence in the company's future prospects, leading to increased buying activity and driving the stock price higher.

29.03.2026 - PRME Stock was down 5.1%

• PRME's third-quarter results suffered wider losses and lower revenues compared to analyst expectations, causing a negative stock movement.
• In the previous quarter, PRME underperformed financially, but saw a positive stock movement due to non-operating income from investments.
• The uncertainty around the upcoming annual shareholder meeting and board elections may have contributed to the bearish market sentiment.
• The continuous poor financial performance and revenue misses are likely undermining investor trust in PRME, leading to the downtrend in the stock price.

09.05.2026 - PRME Stock was down 5.1%

• Concerns have arisen among investors due to the issuance of 75,000 stock options to multiple directors at Prime Medicine, possibly impacting the stock price by diluting existing shares.
• The stock options grant may be viewed by investors as a lack of short-term confidence in the company, which could be contributing to the current bearish movement.
• The rise in derivative securities holdings by directors might indicate a misalignment between management and shareholders, resulting in diminished investor confidence and a decrease in the stock's value.

11.04.2026 - PRME Stock was up 5.9%

• Despite reporting a Q1 loss and missing revenue estimates, Prime Medicine (PRME) experienced a bullish market movement today.
• The bullish trend could be attributed to the company's strategic initiatives, such as appointing new executives, initiating equity offerings, and prioritizing its liver disease programs.
• Analysts forecasting significant revenue growth and a higher price target for PRME might have also contributed to the positive market sentiment.
• Investors seem optimistic about Prime Medicine's gene-editing pipeline progress, promising preclinical data, and ongoing regulatory efforts, leading to the bullish movement in the stock.